2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

gastric parietal cells

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

5

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17021
    Esomeprazole
    3 Publications Verification

    (S)-Omeprazole; (-)-Omeprazole

    		 Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole
  • HY-17023
    Esomeprazole sodium
    2 Publications Verification

    (S)-Omeprazole sodium; (-)-Omeprazole sodium

    		 Exosomes Proton Pump Bacterial Endocrinology Cancer
    Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole sodium
  • HY-101664
    Ilaprazole

    IY-81149

    		 Proton Pump TOPK Inflammation/Immunology Cancer
    Ilaprazole (IY-81149) is an orally active proton pump inhibitor. Ilaprazole irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole
  • HY-B2145
    Ilaprazole sodium

    IY-81149 sodium

    		 Proton Pump TOPK Inflammation/Immunology Cancer
    Ilaprazole (IY-81149) sodium is an orally active proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole sodium
  • HY-115822
    α-Fluoromethylhistidine dihydrochloride

    		Amino Acid Decarboxylase Neurological Disease Metabolic Disease
    α-Fluoromethylhistidine dihydrochloride is an orally active histidine decarboxylase inhibitor. α-Fluoromethylhistidine dihydrochloride depletes histamine in enterochromaffin-like (ECL) cells, reduces the number and volume density of secretory vesicles in ECL cells, and does not affect histamine storage in mast cells. α-Fluoromethylhistidine dihydrochloride abolishes Omeprazole (HY-B0113)-induced vacuolization of ECL cells and decreases gastrin-induced histamine efflux from ECL cells. α-Fluoromethylhistidine dihydrochloride does not alter the granular characteristics of ECL cells, omeprazole-induced hypertrophy of ECL cells, gastrin-induced pancreastatin-like immunoreactivity efflux, nor does it affect gastric acid secretion induced by histamine or vagal stimulation. α-Fluoromethylhistidine dihydrochloride inhibits basal and gastrin-stimulated gastric acid secretion, reduces acid output induced by gastrin+IBMX (HY-12318), but does not directly affect acid generation in isolated parietal cells .
    α-Fluoromethylhistidine dihydrochloride
  • HY-17021B
    Esomeprazole potassium salt
    2 Publications Verification

    (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt

    		 Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole potassium salt
  • HY-W1015419
    α-FMH

    α-Fluoromethylhistidine

    		 Amino Acid Decarboxylase Cardiovascular Disease Neurological Disease
    α-FMH (α-Fluoromethylhistidine) is an orally active histidine decarboxylase inhibitor. α-FMH depletes histamine in enterochromaffin-like (ECL) cells, reduces the number and volume density of secretory vesicles in ECL cells, and does not affect histamine storage in mast cells. α-FMH abolishes Omeprazole (HY-B0113)-induced vacuolization of ECL cells and decreases gastrin-induced histamine efflux from ECL cells. α-FMH does not alter the granular characteristics of ECL cells, omeprazole-induced hypertrophy of ECL cells, gastrin-induced pancreastatin-like immunoreactivity efflux, nor does it affect gastric acid secretion induced by histamine or vagal stimulation. α-FMH inhibits basal and gastrin-stimulated gastric acid secretion, reduces acid output induced by gastrin+IBMX (HY-12318), but does not directly affect acid generation in isolated parietal cells .
    α-FMH
  • HY-17021A
    Esomeprazole magnesium salt

    (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt

    		 Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole magnesium salt
  • HY-17021S1
    Esomeprazole-d3

    (S)-Omeprazole-d3; (-)-Omeprazole-d3

    		 Isotope-Labeled Compounds Proton Pump Inflammation/Immunology Endocrinology Cancer
    Esomeprazole-d3 is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole-d3
  • HY-17021R
    Esomeprazole (Standard)

    (S)-Omeprazole (Standard); (-)-Omeprazole (Standard)

    		 Reference Standards Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole (Standard) is the analytical standard of Esomeprazole. This product is intended for research and analytical applications. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole (Standard)
  • HY-19105A
    IT 066 hydrochloride

    		Histamine Receptor Inflammation/Immunology
    IT 066 hydrochloride is a Histamine H2 receptor antagonist. IT 066 hydrochloride possesses antioxidant activity and can protect rats against acute gastric mucosal injury induced by ischemia-reperfusion. IT 066 hydrochloride can also inhibit secretagogue-induced gastric acid secretion in rats and exert a long-acting anti-lesion effect on experimental gastric and duodenal lesions in rats. IT 066 hydrochloride is applicable for the research of gastrointestinal diseases .
    IT 066 hydrochloride
  • HY-17023R
    Esomeprazole sodium (Standard)

    (S)-Omeprazole sodium (Standard); (-)-Omeprazole sodium (Standard)

    		 Reference Standards Exosomes Proton Pump Bacterial Endocrinology Cancer
    Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole sodium (Standard)
  • HY-19106
    MCI-727 free base

    		Secretin Receptor Inflammation/Immunology Endocrinology
    MCI-727 free base is an orally active anti-ulcer agent. MCI-727 free base can increase the plasma secretin concentration in rats and dogs. MCI-727 free base can also stimulate the exocrine function of the pancreas in rats by promoting the release of endogenous secretin, and exert preventive and therapeutic effects on mild acute pancreatitis. MCI-727 free base can be used in the research of ulcer-related diseases .
    MCI-727 free base
  • HY-17023S
    Esomeprazole-d6 sodium

    (S)-Omeprazole-d6 sodium; (-)-Omeprazole-d6 sodium

    		 Isotope-Labeled Compounds Proton Pump Others
    Esomeprazole-d6 sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole-d6 sodium
  • HY-15541
    Zaltidine

    CP-57361

    		 Histamine Receptor Endocrinology
    Zaltidine dihydrochloride (CP-5736 dihydrochloride) is a highly specific H2 receptor antagonist with antisecretion activity. Zaltidine dihydrochloride reduces the stimulant effect of histamine on gastric acid secretion by binding to histamine H2 receptors on gastric parietal cells, thus reducing gastric acid production. Zaltidine dihydrochloride can be used in the study of gastric acid-related diseases such as duodenal ulcers .
    Zaltidine
  • HY-15541A
    Zaltidine dihydrochloride

    CP-5736 dihydrochloride

    		 Histamine Receptor Endocrinology
    Zaltidine (CP-5736) dihydrochloride is a highly specific H2 receptor antagonist with antisecretion activity. Zaltidine dihydrochloride reduces the stimulant effect of histamine on gastric acid secretion by binding to histamine H2 receptors on gastric parietal cells, thus reducing gastric acid production. Zaltidine dihydrochloride can be used in the study of gastric acid-related diseases such as duodenal ulcers .
    Zaltidine dihydrochloride
  • HY-17021C
    Esomeprazole hemistrontium

    (S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium

    		 Proton Pump Bacterial Inflammation/Immunology Endocrinology Cancer
    Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole hemistrontium
  • HY-W719463
    Rabeprazole sulfide-d4

    		Isotope-Labeled Compounds Proton Pump Bacterial Infection
    Rabeprazole sulfide-d4 is the deuterium labeled Rabeprazole Sulfide (HY-W003467). Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H+/K+)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment .
    Rabeprazole sulfide-d4
  • HY-17021S
    Esomeprazole-d3 sodium

    (S)-Omeprazole-d3 sodium; (-)-Omeprazole-d3 sodium

    		 Isotope-Labeled Compounds Proton Pump Inflammation/Immunology Endocrinology Cancer
    Esomeprazole-d3 (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole-d3 sodium
  • HY-B2145A
    Ilaprazole sodium hydrate

    IY-81149 sodium hydrate

    		 Proton Pump TOPK Inflammation/Immunology Cancer
    Ilaprazole (IY-81149) sodium hydrate is an orally active proton pump inhibitor. Ilaprazole sodium hydrate irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium hydrate is used for the research of gastric ulcers. Ilaprazole sodium hydrate is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole sodium hydrate
  • HY-17021S2
    Esomeprazole-d3 potassium

    (S)-Omeprazole-d3 potassium; (-)-Omeprazole-d3 potassium

    		 Bacterial Proton Pump Isotope-Labeled Compounds Inflammation/Immunology Endocrinology Cancer
    Esomeprazole-d3 potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
    Esomeprazole-d3 potassium
  • HY-177424
    Eprazole trisulfide dimer

    		Proton Pump Others
    Eprazole trisulfide dimer is a trisulfide dimer of Ilaprazole (HY-101664), an orally active proton pump inhibitor that irreversibly inhibits H+/K+-ATPase in a dose-dependent manner with an IC50 of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Eprazole trisulfide dimer can be utilized in research on gastric ulcers .
    Eprazole trisulfide dimer
  • HY-B2145R
    Ilaprazole sodium (Standard)

    IY-81149 sodium (Standard)

    		 Proton Pump TOPK Reference Standards Inflammation/Immunology Cancer
    Ilaprazole (sodium) (Standard) is the analytical standard of Ilaprazole (sodium). This product is intended for research and analytical applications. Ilaprazole (IY-81149) sodium is an orally active proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H+/K+-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole sodium (Standard)
  • HY-101664R
    Ilaprazole (Standard)

    IY-81149 (Standard)

    		 Reference Standards Proton Pump TOPK Inflammation/Immunology Cancer
    Ilaprazole (Standard) is the analytical standard of Ilaprazole. This product is intended for research and analytical applications. Ilaprazole (IY-81149) is an orally active proton pump inhibitor. Ilaprazole irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: